Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Adjuvant to Ablation in Recurrent HCC
NCT05240404Phase 2Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Disease-free survival at 3 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05240404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240404.